The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy

International Journal of Obesity

Volumn 40, Issue 9, 2016, Pages 1369-1375

  Fujioka, K ^a   Plodkowski, R ^a   O'Neil, P M ^b   Gilder, K ^c   Walsh, B ^c   Greenway, F L ^d  

^a SCRIPPS CLINIC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Orexigen Therapeutics Inc   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE; ANTIOBESITY AGENT; NALTREXONE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; BODY WEIGHT MANAGEMENT; COMBINATION DRUG THERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; BODY WEIGHT LOSS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; BUPROPION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; OBESITY; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84981275631     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2016.67     Document Type: Article

References (24)

1. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA et al. 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129 (suppl 2): S102-S138.
2. Wadden TA, Volger S, Tsai AG, Sarwer DB, Berkowitz RI, Diewald LK et al. Managing obesity in primary care practice: an overview with perspective from the POWER-UP study. Int J Obes 2013; 37 (Suppl 1): S3-11.
3. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014; 95: 53-66.
4. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311: 74-86.
5. Unick JL, Hogan PE, Neiberg RH, Cheskin LJ, Dutton GR, Evans-Hudnall G et al. Evaluation of early weight loss thresholds for identifying nonresponders to an intensive lifestyle intervention. Obesity 2014; 22: 1608-1616.
6. Rissanen A, Lean M, Rossner S, Segal KR, Sjostrom L. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003; 27: 103-109.
7. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006; 8: 206-213.
8. Prescribing Information: Belviq (lorcaserin hydrochloride) tablets. In: Eisai Inc., 2013.
9. Prescribing Information: Qsymia (phentermine and topiramate extended-release) capsule. In: Vivus, Inc., 2014.
10. Prescribing Information: Contrave (naltrexone HCl and bupropion HCl) Extendedrelease Tablets. In: Takeda Pharmaceuticals America, Inc., 2014.
11. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
12. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013; 21: 935-943.
13. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 2011; 19: 110-120.
14. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36: 4022-4029.
15. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012; 367: 1577-1579.
16. Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601.
17. Moyer VA. US Preventive Services Task Force Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 373-378.
18. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 186-194.
19. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity 2014; 22 (Suppl 2): S41-S410.
20. Look Ahead Research Group, Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-1383.
21. Foster GD, Sanders MH, Millman R, Zammit G, Borradaile KE, Newman AB et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 2009; 32: 1017-1019.
22. Phelan S, Kanaya AM, Subak LL, Hogan PE, Espeland MA, Wing RR et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol 2012; 187: 939-944.
23. Williamson DA, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K et al. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med 2009; 169: 163-171.
24. Diabetes Prevention Program Research G, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.